↓ Skip to main content

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer

Overview of attention for article published in Drug Design, Development and Therapy, March 2011
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
137 Dimensions

Readers on

mendeley
155 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Published in
Drug Design, Development and Therapy, March 2011
DOI 10.2147/dddt.s13029
Pubmed ID
Authors

Emmanuel Antonarakis, Paller

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 155 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 <1%
Unknown 154 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 27 17%
Student > Bachelor 26 17%
Student > Ph. D. Student 24 15%
Student > Master 23 15%
Student > Postgraduate 10 6%
Other 24 15%
Unknown 21 14%
Readers by discipline Count As %
Medicine and Dentistry 40 26%
Agricultural and Biological Sciences 28 18%
Biochemistry, Genetics and Molecular Biology 19 12%
Chemistry 11 7%
Pharmacology, Toxicology and Pharmaceutical Science 8 5%
Other 22 14%
Unknown 27 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 June 2015.
All research outputs
#4,332,397
of 8,163,518 outputs
Outputs from Drug Design, Development and Therapy
#395
of 1,036 outputs
Outputs of similar age
#120,752
of 239,654 outputs
Outputs of similar age from Drug Design, Development and Therapy
#19
of 43 outputs
Altmetric has tracked 8,163,518 research outputs across all sources so far. This one is in the 27th percentile – i.e., 27% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,036 research outputs from this source. They receive a mean Attention Score of 3.8. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,654 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.